Elligo Health Research
Elligo Health Research is recorded as a service provider in 21 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 21 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-4)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome
Sponsor Longboard Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination compared to Fluticasone Propionate, Albuterol Sulfate or Placebo delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older with Asthma
Sponsor Teva Branded Pharmaceutical Products R&D LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies
Sponsor Longboard Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Sponsor Dicerna Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy
Sponsor Longboard Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
Sponsor Priovant Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)
Sponsor Anthos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-2)
Sponsor Karuna Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis
Sponsor Dicerna Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants with Dementia of the Alzheimer's Type
Sponsor Suven Life Sciences Limited
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor Avidity Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABEL EXTENSION
Sponsor Zogenix International Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Elligo Health Research?
The 2026-10-09 snapshot links Elligo Health Research to 21 distinct CTIS trials. Recorded services include Patient recruitment and website, promo items, Patient travel reimbursement, clinical study branding, patient print materials, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Elligo Health Research?
The most frequently recorded therapeutic areas are Neurology, Genetic and Congenital Disorders, Immunology, Musculoskeletal. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Elligo Health Research conducted?
The linked trials record locations in 25 countries, including Spain, Germany, Italy, France, Netherlands. These are trial locations, not confirmed office locations or countries where Elligo Health Research delivered services.
What can this page tell me about Elligo Health Research's trial experience?
Browse 21 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Elligo Health Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Elligo Health Research Inc.